Athena Athena

X
[{"orgOrder":0,"company":"Theolytics","sponsor":"Epidarex Capital","pharmaFlowCategory":"D","amount":"$6.8 million","upfrontCash":"Undisclosed","newsHeadline":"Theolytics Raises $6.8 million Series A Round Co-Led by Epidarex Capital and Taiho Ventures to Advance Viral Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Theolytics","sponsor":"M Ventures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Theolytics Expands Series A Financing and Welcomes M Ventures as a New Investor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Theolytics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theolytics Presents CAF-Targeting Therapy For Stromal Rich Tumours, And Strengthens Leadership Team","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Theolytics

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            THEO-260 is a new oncolytic virus in development that is intrinsically capable of targeted killing of both cancer cells and cancer associated fibroblasts (CAFs).

            Lead Product(s): THEO-260

            Therapeutic Area: Oncology Product Name: THEO-260

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 06, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The expanded Series A funding will support the progress of internal programmes in ovarian cancer, and a second cancer indication in addition to further advancing the company's unique technology platforms.

            Lead Product(s): Oncolytic Viral Therapies

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: M Ventures

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Series A Financing July 08, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The financing will be used to progress the company’s Oncolytic viral therapies towards human clinical trials.

            Lead Product(s): Oncolytic viral therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Epidarex Capital

            Deal Size: $6.8 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing January 07, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY